Brief: Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies
07/11/2022 14:18
Nov 7 (Reuters) - Nkarta Inc NKTX.O :
* NKARTA PRESENTS DATA SUPPORTING ENGINEERED NK CELL BASED
COMBINATION THERAPIES AND NEXT GENERATION COMMERCIAL-SCALE
MANUFACTURING PLATFORM AT SITC 37TH ANNUAL MEETING
* NKARTA INC - IMPROVED ANTI-TUMOR ACTIVITY DEMONSTRATED BY
COMBINATION OF NKX019 AND A CD20-DIRECTED MONOCLONAL ANTIBODY IN
PRECLINICAL MODELS
Source text for Eikon: ID:nGNXgvg3l
Further company coverage: NKTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Nkarta
See all newsNkarta, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Brief: Nkarta Q2 EPS USD -0.54
Nkarta, Inc. expected to post a loss of 38 cents a share - Earnings Preview
Biotech experts want FDA drug reviews based on science, not politics (updated)